This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- LAZCLUZE (lazertinib) is a kinase inhibitor indicated in combination with RYBREVANT (amivantamab-vmjw) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (Exon19del) or Exon 21 L858R substitution mutations, as detected by a United States Food and Drug Administration (FDA)-approved test.1
- LAZCLUZE is not commercially available as a solution or suspension.
- LAZCLUZE 80 mg or 240 mg tablet(s) can be dispersed in non-carbonated water for patients needing nasogastric tube administration.1
- The company cannot support any practices, procedures, or dosage administration techniques that deviate from the approved product labeling.
- Please refer to the DOSAGE AND ADMINISTRATION section of the full Prescribing Information for complete information.1
Alternate Method of PREPARATION AND ADMINISTRATION
LAZCLUZE Tablets Prepared as a Dispersion for Nasogastric Tube Administration1
- Place the tablet(s) required for the prescribed dose of LAZCLUZE into the barrel of a 20 mL syringe and draw up noncarbonated water to the 20 mL graduation mark. Do not crush or split the tablet(s).
- Close the syringe with the tipcap and keep the syringe at room temperature for 5 minutes.
- After 5 minutes, rotate the syringe back and forth 15 times until the tablet(s) are dispersed into small pieces.
- Administer immediately through the nasogastric tube 8 French or greater.
- Flush the syringe twice with 10 mL of noncarbonated water through the nasogastric tube to ensure that the full dose is administered.
- Discard any unused dispersion if not administered within 1 hour of preparation.
Literature Search
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 13 November 2026.